GTCbio conferences aim to facilitate transformational platforms that would have a significant impact on scientific research, drug development and healthcare. Identifying and validating new targets is a critical starting point and often times a daunting inflection point in drug development. While there is continuous innovation and invention of new assays and screening technologies, it is important to understand how these technologies will help with new and existing targets. Protein Kinases have long been an important target in several diseases and we will discuss new developments in this area at our 2018 Enzymes in Drug Discovery Summit. We will also focus on advances in Ubiquitin and Protease targeted therapies.
Please join us to be part of an exciting platform at the Enzymes in Drug Discovery Summit, which will take place February 22-23, 2018 in San Diego, CA.
This summit will feature the following four targeted areas:
Protein Kinases in Drug Discovery
- Novel Approaches, Tools and Technologies in Kinase Drug Discovery
- Kinome Selectivity & Clinical Translation
Ubiquitin Research & Drug Discovery
- Novel Drug Targets in the Ubiquitin System
- Advances in Ubiquitin-like Modifications
Epigenetic Enzymes in Drug Discovery
- Epigenetic Modification & Transcriptional Regulation
- Novel Therapeutic Targets & Translational Studies
Protease Inhibitors in Drug Discovery
- Chemistry and Drug Design for Protease Inhibitors
- Protease Inhibitors in Translational Research
|Matthew Bogyo |
Professor, Department of Pathology
|Judith Clements |
Queensland University of Technology
|Jack Taunton |
Professor, Cellular and Molecular Pharmacology, Pharmaceutical Chemistry
University of California, San Francisco
In addition to scientific presentations, dedicated networking sessions will allow you to connect and form new relationships with colleagues from both the private and public sector.
We hope to see you there!
The 2018 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Ubiquigent provides access to the necessary expertise, chemistry (recently launching DUBtarget™-001, a deubiquitylase targeted hit-finding library), high quality research tools and integrated and collaborative drug discovery services required to support our commercial and academic partners in pursuing ubiquitin system-focused drug discovery programmes, and in undertaking basic research.
Nanome has designed an innovative software solution that leverages Virtual Reality to provide scientists with an immersive tool for collaborative molecular visualization, drug discovery, and drug design. Imagine being able to invite your colleagues to an environment where you can explore, manipulate, analyze small molecules or macro-molecular structures together in 3-D. For more information please come try our software or visit www.nanome.ai
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.